Furthermore, we demonstrated an enhanced leukaemia suppression of an AML cell line xenograft model using FLT3‐ITD ASO loaded CD33‐targeting RBCEVs and in patient‐derived xenograft models of AML using miR‐125b ASO loaded CD33‐targeting RBCEVs. The gene discussed is CD33; the disease is acute myeloid leukemia.